Essential Partners’s Context Therapeutics CNTX Stock Holding History

Essential Partners’s Portfolio CNTX Stock Details CNTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$69	Buy	+231	New	+$114	﹤0.01%	2735

Other funds holding CNTX

TGY2IT

Timothy G. Youngquist 2020 Irrevocable Trust Fort Myers, Florida $530M AUM 95.29% 1-Year Est. Return

Axxcess Wealth Management Carlsbad, California $2.44B AUM 16.42% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Anchyra Partners Atlanta, Georgia $477M AUM 34.33% 1-Year Est. Return

GAMMA Investing Foster City, California $2.96B AUM 34.38% 1-Year Est. Return

FNY Investment Advisers New York $402M AUM 85.9% 1-Year Est. Return

Sterling Capital Management Charlotte, North Carolina $4.92B AUM 24.73% 1-Year Est. Return

Farther Finance Advisors San Francisco, California $14.2B AUM 18.33% 1-Year Est. Return

SBI Securities Tokyo, Japan $4.38B AUM 56.37% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

Essential Partners's CNTX Position: Q3 2026 in Review

Essential Partners opened a new position in Context Therapeutics (CNTX) in Q3 2026: 231 shares worth $69. The stake represents ﹤0.01% of the portfolio and ranks #2735 among its holdings.

11 funds tracked by Wall St. Rank hold CNTX as of Q3 2026.

Essential Partners held 231 shares of Context Therapeutics worth $69 as of Q3 2026.
Context Therapeutics was a new Essential Partners position in Q3 2026.
Context Therapeutics made up ﹤0.01% of Essential Partners's portfolio in Q3 2026, its #2735 holding.
11 funds tracked by Wall St. Rank held Context Therapeutics as of Q3 2026.

Based on Essential Partners's 13F filing for Q3 2026, filed 14 Oct 2026.